Market Newsdesk

Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology

— Early data from ongoing PROTECT trial suggest stable and durable response to KRYSTEXXA® (pegloticase injection) therapy in treating uncontrolled gout among people with kidney transplants —

— Data on the company’s investigational compound (HZN-4920) under evaluation for rheumatoid arthritis will be presented during an oral session on June 3 at 10:15 a.m. CEST —

DUBLIN–(BUSINESS WIRE)–
Horizon Therapeutics plc (Nasdaq: HZNP) today presented new data during the EULAR European Congress of Rheumatology from the ongoing PROTECT study, which provides further insight into utility of KRYSTEXXA (pegloticase injection) as a treatment for people with uncontrolled gout (chronic gout refractory to conventional therapies) who have undergone a kidney transplant.

The Prospective Study of Pegloticase in Transplant patients (PROTECT) trial is an ongoing Phase 4, multi-site, open-label trial evaluating the safety and efficacy of KRYSTEXXA in adults with uncontrolled gout who have received a kidney transplant and are on stable immunosuppressive therapy. Participants are receiving KRYSTEXXA (8 mg once every two weeks for 24 weeks) to determine response rate (defined as serum uric acid (sUA) <6 mg/dL for at least 80 percent of the time) during Month 6.¹

At time of data cut, estimated glomerular filtration rate (eGFR), a key indicator of kidney function, remained stable for all patients throughout KRYSTEXXA treatment. In the 10 patients with Week 24 eGFR measurements, the mean eGFR was 41.6 ± 10.6 mL/min/1.73 m² (median of 41.0) at baseline and 43.8 ± 11.9 mL/min/1.73 m² (median of 46.6) at Week 24, with a mean improvement of 2.3 ± 8.1 mL/min/1.73 m² during the treatment. Further, through health assessment questionnaires, patients reported clinically meaningful reductions in pain (average reduction of 26.7 +/- 30.3 from baseline of 35.9 +/- 30.2 on a scale of 0-100) and disability (average reduction of 0.2 +/- 0.5 from baseline of 1.0 +/- 1.0 on a scale of 0-3).

“Given kidney transplant patients have a 10-fold or higher prevalence of gout compared to non-transplant patients, it is particularly important to effectively manage this disease,” said Abdul Abdellatif, M.D. F.A.S.N. primary investigator and adjunct assistant professor, Baylor College of Medicine Nephrology Division, and Kidney Hypertension Transplant Clinic of Clearlake Specialties. “Expanding datasets from the PROTECT trial indicated that KRYSTEXXA could represent a durable and tolerable therapy for this sensitive patient population.”

The PROTECT trial was fully enrolled in January 2021 with 20 patients who received a kidney transplant and as such were on two to three immunosuppressive agents each. At the time of data analysis, 10 patients had completed the full course of therapy and five were receiving ongoing treatment; three patients discontinued the study (one withdrew consent, two withdrew due to COVID-19 concerns) and two discontinued treatment due to meeting sUA monitoring protocols. In the trial, 15 patients experienced an adverse event, with the majority (12 of 15 patients) reporting mild-to-moderate events, none of which led to discontinuation of therapy. No anaphylaxis or infusion reaction events were reported. The trial is expected to be completed in Fall 2021. Preliminary findings of the PROTECT clinical trial: pegloticase efficacy and safety in kidney transplant recipients (Abstract: POS1122)

“The persistent challenge of a chronic disease like gout requires that we understand how the experience varies among patient populations, especially more vulnerable populations like kidney transplant recipients, and design regimens accordingly to meet treatment goals,” said Jeffrey D. Kent, M.D., FACG, FACP, executive vice president, medical affairs and outcomes research, Horizon. “The data we continue to collect through robust research programs on KRYSTEXXA provides not only clarity on the role of this important therapy, but also confidence to physicians that this can support holistic patient care.”

Additional KRYSTEXXA Presentations

Other KRYSTEXXA presentations during EULAR include posters highlighting the pharmacokinetic and anti-drug antibody profile when KRYSTEXXA is co-administered with methotrexate as part of the MIRROR open-label trial (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate [Abstract POS1136]), as well as real world insights on the demographics, comorbidities and renal functions of people who received KRYSTEXXA (Demographics, Comorbidities, and Renal Function of Uncontrolled Gout Patients Who Received Pegloticase: Finding From A Large US Claims Database [Abstract POS1121]). Notably, data from the U.S. claims database found that 83 percent (40 of 48) of people who had a full course of treatment captured experienced stable or improved chronic kidney disease. For people with advanced chronic kidney disease (Stages 3- 5), data showed that 89 percent (16 of 18 people) experienced stable or improved chronic kidney disease.

Oral Presentation on HZN-4920

Additionally, during an oral session on June 3, 2021 at 10:15 a.m. CEST, the company will present data assessing the duration of clinical improvement beyond Day 169 of its original 2019 trial of people with moderate-to-severe rheumatoid arthritis (RA). This observational follow-up study of 16 out of 24 patients, who had received 1000 mg or 1500 mg HZN-4920 at one of two sites in Poland, showed that HZN-4920 added to stable DMARD therapy may provide a prolonged, clinically meaningful benefit to patients with moderate to severe RA. Duration of clinically meaningful benefit was assessed by need for rescue therapy. Interpretation of these data is limited. The duration of clinical response needs to be confirmed in prospective, double-blind, placebo-controlled studies. (Duration of Clinical Efficacy Following Treatment with VIB4920 in Subjects with Moderate to Severe Rheumatoid Arthritis (Abstract: OP0120)

About HZN4920

This investigational compound is a fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. Horizon is currently conducting Phase 2 clinical trials with HZN4920 in Sjögren’s syndrome, rheumatoid arthritis and kidney transplant rejection.

About KRYSTEXXA

INDICATIONS AND USAGE

KRYSTEXXA® (pegloticase injection) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.

Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS

Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. Serum uric acid levels should be monitored prior to infusions, and healthcare providers should consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.

The risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response.

Concomitant use of KRYSTEXXA and oral urate-lowering agents may blunt the rise of sUA levels. Patients should discontinue oral urate-lowering agents and not institute therapy with oral urate-lowering agents while taking KRYSTEXXA.

In the event of anaphylaxis or infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate.

Patients should be informed of the symptoms and signs of anaphylaxis and instructed to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting.

CONTRAINDICATIONS: G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

Patients should be screened for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. KRYSTEXXA should not be administered to these patients.

GOUT FLARES

An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including treatment with KRYSTEXXA. If a gout flare occurs during treatment, KRYSTEXXA need not be discontinued. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.

CONGESTIVE HEART FAILURE

KRYSTEXXA has not been studied in patients with congestive heart failure, but some patients in the clinical trials experienced exacerbation. Caution should be exercised when using KRYSTEXXA in patients who have congestive heart failure, and patients should be monitored closely following infusion.

ADVERSE REACTIONS

The most commonly reported adverse reactions in clinical trials with KRYSTEXXA were gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis and vomiting.

Please see Full Prescribing Information and Medication Guide for more information.

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the potential benefits of KRYSTEXXA and HZN-4920 and expectations regarding the PROTECT clinical trial. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, risks regarding whether future results of the PROTECT clinical trial and on-going Phase 2 clinical trials of HZN-4920 will be consistent with preliminary results or results of prior trials or other data or Horizon’s expectations, the risks associated with clinical development of drug candidates and risks related to competition or other factors that may change physician treatment strategies. For a further description of these and other risks facing Horizon, please see the risk factors described in Horizon’s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in those filings. Forward-looking statements speak only as of the date of this press release and Horizon undertakes no obligation to update or revise these statements, except as may be required by law.

References:

1. National Institutes of Health. Study of Pegloticase in Patients with Uncontrolled Gout Who Have Had a Kidney Transplant. https://clinicaltrials.gov/ct2/show/NCT04087720. Accessed May 25, 2021.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005224/en/

Tina Ventura

Senior Vice President, Investor Relations

[email protected]

Ruth Venning

Executive Director, Investor Relations

[email protected]

U.S. Media Contact:

Amanda Phraner

Director, Product Communications

[email protected]

Ireland Media Contact:

Gordon MRM

Ray Gordon

[email protected]

KEYWORDS: Europe Ireland United States North America Illinois

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Medical Supplies Health Medical Devices Clinical Trials

MEDIA:

Logo

Seagen to Present at the Goldman Sachs 42^nd Annual Global Healthcare Conference

BOTHELL, Wash.–(BUSINESS WIRE)–
Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Goldman Sachs 42^nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 2:10 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seagen’s website at www.seagen.com in the Investors section.

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005198/en/

Peggy Pinkston

(425) 527-4160

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

Circa Resort and Casino Standardizes on Aruba to Deliver Transcendent Guest Experiences

New 1.25 Million-Square-Foot Downtown Las Vegas Hotel Deploys a Secure Aruba ESP-based Network to Power Massive HD Displays, a Three-story Sportsbook, Garage Mahal, and Other Amenities

SANTA CLARA, Calif.–(BUSINESS WIRE)–
Aruba, a Hewlett Packard Enterprise company (NYSE: HPE), today announced that Circa Resort and Casino, the first new downtown Las Vegas hotel and entertainment venue in over 40 years, has selected an end-to-end Aruba ESP-based network to deliver unique, immersive and engaging experiences at the 35-story, 777-room sports-themed property, as well as to satellite locations throughout Nevada, Colorado, and other jurisdictions, while saving nearly half a million dollars.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005188/en/

To create an energetic and transcendent atmosphere that draws on the original spirit of Las Vegas and updated for the digital age, Circa is using a combination of Aruba’s wired, wireless and security solutions to provide the performance and bandwidth required to power its unique amenities. This includes the Stadium Swim, a pool deck with amphitheater-style lounging terraces facing a 143-foot video display, and a three-story Sportsbook, featuring a 78 million pixel video display divided into 42 screens with a 1,000-person viewing capacity.

In collaboration with trusted integration partner Evotek, Circa evaluated prominent networking competitors including Cisco, Juniper, and Ruckus, as well as Aruba, to gain an intelligent, reliable, and flexible network. Ultimately, Aruba offered the most comprehensive, automated solution for helping Circa bring its hospitality vision to life.

“Delivering today’s socially driven premier entertainment experiences in Las Vegas is a 24/7 endeavor,” said Paul Ballard, CIO at Circa. “Aruba supplied the full stack of AI-enabled wired and wireless networking innovations essential for running a successful operation.”

Working with Evotek, Circa deployed a future-ready wireless network comprised of Aruba’s Wi-Fi 6 indoor access points (APs), outdoor APs, hospitality APs, and mobility controllers. For wired networking, Circa implemented Aruba’s aggregation switches at the edge and CX Series switches in the data center.

Beyond enabling onsite multicasting, Circa is providing modern in-room experiences such as connected lighting and IP TVs. “Deploying Aruba’s wireless to guest rooms not only addresses user expectations, it also saved us nearly $500,000 versus installing a gigabyte passive optical network (GPON),” said Ballard. “Aruba’s licensing model was also significantly more attractive.”

To unify and streamline wired and wireless administration, Circa adopted AirWave for network management along with ClearPass for network access control (NAC) and policy management. The company also implemented User Experience Insight (UXI) for Wi-Fi incident detection using AIOps to pinpoint issues that require immediate attention.

“In addition to supporting unparalleled guest experiences, digital employee solutions, and IoT-enabled building maintenance systems, we supply network connectivity to thousands of third-party vendors,” said John Palma, manager of Information Technology Network Engineering at Circa. “Whether it’s mobile POS in our dining areas or digital gaming systems in our casino spaces, Aruba ensures we have the ability to apply consistent policies and granular security to visualize, automate, and control who accesses our network.”

Circa’s new network also supports digital experiences in the resort’s Garage Mahal transportation hub. The facility includes purpose-built solutions for hosting ride-sharing providers and will eventually serve as the downtown terminal for the Boring Company’s Vegas Loop project seeking to outfit Las Vegas with high-speed transportation tunnels.

“With our Aruba network, we can provide Wi-Fi to our guests and to transportation providers in Garage Mahal, as well as deploy the latest in security solutions and connected elevators to help keep everyone safe in transit,” Palma said.

According to Ballard, another considerable benefit of partnering with Aruba is superior technical support. “The challenges of opening a new property during a pandemic can’t be understated,” he said. “No matter what time of day or night, Aruba provided us the right level of support resources for resolving issues quickly, which helped us stay on track to meet our opening day timeline.”

Moving forward, Circa will continue evaluating Aruba solutions that include AIOps, data-driven analytics, and other innovations. “Overall, our Aruba partnership gives us the flexibility to quickly take advantage of new business opportunities,” said Ballard. “This helps us distinguish ourselves from others in Las Vegas, which is a significant competitive advantage.”

About Aruba, a Hewlett Packard Enterprise company

Aruba, a Hewlett Packard Enterprise company, is the global leader in secure, intelligent edge-to-cloud networking solutions that use AI to automate the network, while harnessing data to drive powerful business outcomes. With Aruba ESP (Edge Services Platform) and as-a-service options, Aruba takes a cloud-native approach to helping customers meet their connectivity, security, and financial requirements across campus, branch, data center, and remote worker environments, covering all aspects of wired, wireless LAN, and wide area networking (WAN).

To learn more, visit Aruba at www.arubanetworks.com. For real-time news updates, follow Aruba on Twitter and Facebook, and for the latest technical discussions on mobility and Aruba products, visit the Airheads Community at community.arubanetworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005188/en/

Kathleen Keith

Aruba, a Hewlett Packard Enterprise company

+1-707-529-4507

[email protected]

Jennifer Miu

Aruba, a Hewlett Packard Enterprise company

+1 650-236-9532

[email protected]

KEYWORDS: California Nevada United States North America

INDUSTRY KEYWORDS: Networks Internet Lodging Travel Data Management Technology Mobile/Wireless Security

MEDIA:

Logo

Photo

Circa Resort and Casino, downtown Las Vegas’ newest hotel and entertainment venue, has selected an Aruba ESP-based network to deliver unique and immersive guest experiences. (Photo: Circa Resort and Casino)

COPT to Present at Nareit’s REITweek: 2021 Virtual Annual Conference

COLUMBIA, Md.–(BUSINESS WIRE)–
Corporate Office Properties Trust (“COPT” or the “Company”) (NYSE: OFC) announced that its President and CEO, Stephen E. Budorick, will provide an update on the Company and participate in a question and answer session at Nareit’s REITweek: 2021 Investor Conference, taking place virtually from June 8-10, 2021. The Company’s presentation will start at 8:00 a.m. Eastern Time on June 8, 2021. A live audio webcast of the presentation and materials encompassing the information provided during the presentation and conference will be available on COPT’s Investors website: https://investors.copt.com/

About COPT

COPT is a REIT that owns, manages, leases, develops and selectively acquires office and data center properties. The majority of its portfolio is in locations that support the United States Government and its contractors, most of whom are engaged in national security, defense and information technology (“IT”) related activities servicing what it believes are growing, durable, priority missions (“Defense/IT Locations”). The Company also owns a portfolio of office properties located in select urban/urban-like submarkets in the Greater Washington, DC/Baltimore region with durable Class-A office fundamentals and characteristics (“Regional Office Properties”). As of March 31, 2021, the Company derived 88% of its core portfolio annualized rental revenue from Defense/IT Locations and 12% from its Regional Office Properties. As of the same date and including 17 properties owned through unconsolidated joint ventures, COPT’s core portfolio of 180 office and data center shell properties encompassed 20.8 million square feet and was 94.9% leased; the Company also owned one wholesale data center with a critical load of 19.25 megawatts that was 86.7% leased.

Forward-Looking Information

This press release may contain “forward-looking” statements, as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are based on the Company’s current expectations, estimates and projections about future events and financial trends affecting the Company. Forward-looking statements can be identified by the use of words such as “may,” “will,” “should,” “could,” “believe,” “anticipate,” “expect,” “estimate,” “plan” or other comparable terminology. Forward-looking statements are inherently subject to risks and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate. Although the Company believes that the expectations, estimates and projections reflected in such forward-looking statements are based on reasonable assumptions at the time made, the Company can give no assurance that these expectations, estimates and projections will be achieved. Future events and actual results may differ materially from those discussed in the forward-looking statements and the Company undertakes no obligation to update or supplement any forward-looking statements.

The areas of risk that may affect these expectations, estimates and projections include, but are not limited to, those risks described in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Source: Corporate Office Properties Trust

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005153/en/

IR Contacts:

Stephanie Krewson-Kelly

443-285-5453

[email protected]

Michelle Layne

443-285-5452

[email protected]

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo

PROS Announces Virtual Investment Conference Schedule for June 2021

HOUSTON–(BUSINESS WIRE)–PROS Holdings, Inc. (NYSE: PRO), a provider of AI-powered solutions that optimize selling in the digital economy, today announced that company management will participate virtually in the following investment conferences in June.

Stifel 2021 Virtual Cross Sector Insight Conference

Andres Reiner, President & CEO, Alex Harrington, VP of Finance, and Belinda Overdeput, Senior Manager, Investor Relations

Tuesday, June 8, 2021 | Virtual Fireside Chat 4:00 PM – 4:30 PM EDT and Investor Meetings

Bank of America 2021 Global Technology Conference

Stefan Schulz, CFO and Belinda Overdeput, Senior Manager, Investor Relations

Wednesday, June 9, 2021 | Virtual Fireside Chat 1:45 PM – 2:20 PM EDT and Investor Meetings

Baird’s 2021 Global Consumer, Technology & Services Conference

Stefan Schulz, CFO and Belinda Overdeput, Senior Manager, Investor Relations

Thursday, June 10, 2021 | Virtual Fireside Chat 10:50 AM – 11:20 AM EDT and Investor Meetings

The fireside chats will be webcast live and available by visiting the Investor Relations section of the company’s website. The replay of the webcast will be archived on the company’s website.

About PROS

PROS Holdings, Inc. (NYSE: PRO) provides AI-powered solutions that optimize selling in the digital economy. PROS solutions make it possible for companies to price, configure, and sell their products and services in an omnichannel environment with speed, precision, and consistency. Our customers, who are leaders in their markets, benefit from decades of data science expertise infused into our industry solutions.

Forward-looking Statements

This press release contains forward-looking statements, including statements about the functionality and benefits of AI-powered solutions to organizations generally as well as the functionality and benefits of PROS software products. The forward-looking statements contained in this press release are based upon PROS historical experience with AI-powered solutions and its current expectations of the benefits of AI-powered solutions for organizations that implement and utilize such software. Factors that could cause actual results to differ materially from those described herein include the addressability of an organization’s AI-powered solution needs, the risks associated with PROS developing and enhancing products with the functionality necessary to deliver the stated results and the risks associated with the complex implementation and maintenance of AI-powered solutions such as PROS software products. Additional information relating to the uncertainty affecting the PROS business is contained in PROS filings with the Securities and Exchange Commission. These forward-looking statements represent PROS expectations as of the date of this press release. Subsequent events may cause these expectations to change, and PROS disclaims any obligations to update or alter these forward-looking statements in the future whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005151/en/

PROS Investor Relations

Belinda Overdeput

713-335-5895

[email protected]

PROS Media Contact

Amanda Parrish

832-924-4731

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Retail Other Professional Services Security Data Management Other Communications Technology Marketing Communications Professional Services Online Retail Other Technology Telecommunications Software Networks Internet Mobile/Wireless

MEDIA:

Logo

Pitney Bowes Expands Lockers Portfolio with Launch of ParcelPoint™ Smart Lockers

Flexible solutions available in both pre-configured and customized options deliver safety, security and convenience

STAMFORD, Conn.–(BUSINESS WIRE)–Pitney Bowes Inc. (NYSE: PBI), a global technology company that provides commerce solutions in the areas of ecommerce, shipping, mailing and financial services, today announced the expansion of its lockers portfolio with the launch of ParcelPoint™ Smart Lockers, a new suite of robust, secure contactless locker solutions unique to Pitney Bowes. Ideal for organizations planning the safe reopening of offices, college campuses and government agencies, these smart lockers give organizations the confidence that every package and asset moving across a location will be delivered safely and securely. Powered by proprietary SaaS software, organizations can remotely manage a single locker or a fleet of lockers across locations, backed up with unrivalled local Pitney Bowes service, support and detailed analytics.

The ParcelPoint Smart Locker portfolio augments existing Pitney Bowes locker technologies and builds on a century of expertise in shipping and mailing, offering businesses a choice of smart locker solutions which best fit their requirements and budget. Express Series smart lockers provide a sophisticated, pre-configured, easy-to-use solution built to meet evolving package and mail volume demands, which can be delivered in four weeks or less¹. With SendSuite® Tracking Online – Pitney Bowes SaaS parcel tracking and processing software – already integrated into the solution, Express Series lockers simplify the end-to-end package and mail management processes.

Plus Series smart lockers are modular and scalable, perfect for organizations with more complex workflows. Delivered in ten weeks or less, Plus Series lockers are individually customized to meet the unique needs of organizations with more extensive parcel workflow, asset management, or with specific space or volume requirements. They can operate standalone, without a tracking software or seamlessly integrate with SendSuite Tracking, SendSuite Tracking Online or with an organization’s existing tracking software.

Kerry Caylor, Vice President, SendTech Parcel and Locker Innovation, Pitney Bowes said, “The global automated parcel locker market is expected to exceed $1.4 billion by 2027, driven by organizations looking for ways to manage the exponential growth in ecommerce and parcel volume. Pitney Bowes ParcelPoint Smart Lockers with powerful SaaS software make it easy for organizations to automate, streamline and digitize their parcel and mail management and deliver a user-friendly contactless pickup experience. By providing the both pre-configured and customized options, we’re giving organizations the choice and flexibility to select the smart locker solution that exactly matches their requirements and the needs of the clients they serve.”

Global parcel volume is forecast to reach 200 billion by 2025, challenging organizations to find ways to simplify package management and optimize resources. As they reopen safely organizations will bring in new safety and security standards, with requirements to limit direct contact and minimize the time parcels are left unclaimed. Pitney Bowes ParcelPoint Smart Lockers solve these challenges, providing a streamlined digital experience, sophisticated functionality and accurate tracking, while meeting growing user expectations. The locker solutions are ideal for organizations with centralized mail centers which manage high volumes of parcels and physical documents, tasked with their safe, secure, effective delivery. Integrating seamlessly into centralized mailroom processes, operators access the smart locker interface from their device to identify an appropriately sized available locker in a suitable location. They place the item in the locker, then an automatic alert with an access barcode is sent to the recipient who scans the barcode and retrieves the package at their convenience. Real-time reporting and analytics ensure absolute visibility of the package’s journey throughout the process.

During the product design process for ParcelPoint Smart Lockers, Pitney Bowes interviewed 200 enterprise and higher education leaders to better understand their barriers to efficient package management. 66 percent of enterprises were concerned about leaving items unattended and 52 percent felt restricted by storage and space constraints. Higher education respondents were also concerned about package security. Now, 88 percent of enterprises and 76 percent of higher education respondents say that lockers have completely alleviated their security concerns, and 72 percent of enterprises say lockers have addressed concerns relating to space and storage.

Smart lockers transform parcel management processes for government agency and university

The State of Louisiana Office of Technology Services (OTS) is tasked with the timely and accurate delivery of mail and parcels to 120 branch state agencies and quasi-agency locations across the Capital area. Prior to the pandemic, a team consisting of six drivers and five operators hand-delivered mail to approximately 1800 delivery points across the state buildings complex. In 2020, the need to avoid direct contact and enable employees to access their mail without entering the building became a priority. Processing more than 2.5 million mail pieces every month, the OTS accelerated its transition from in-person mail delivery to smart locker technology from Pitney Bowes. OTS said, “Now, we have security, accountability and tracking. Tenants love the service and the convenience of the locker system, and we love the ease-of-use, generous screen size, quick configuration and installation.”

Washburn University is a public university in Kansas with just under 7000 students. The pandemic accelerated the need for contactless experiences across the campus to ensure the health and safety of students and staff. The university also wanted to deliver a better university bookstore experience. Pitney Bowes delivered a solution that would allow students the ability to buy online and pick up from a smart locker. Now, students are able to place their bookstore orders online and pick up their items when it’s convenient with the scan of a simple barcode. The university also uses the lockers for different campus needs such as returning students’ items from Lost and Found to their owners.

To find out more, listen to ‘Modernizing Processes with Contactless Delivery’ here. For insights on the future of work and return to the office, catch up on our recent webinar here.

¹ Delivery outside of the contiguous U.S. may take longer than four weeks

About Pitney Bowes

Pitney Bowes (NYSE:PBI) is a global technology company providing commerce solutions that power billions of transactions. Clients around the world, including 90 percent of the Fortune 500, rely on the accuracy and precision delivered by Pitney Bowes solutions, analytics, and APIs in the areas of ecommerce fulfillment, shipping and returns; cross-border ecommerce; office mailing and shipping; presort services; and financing. For 100 years Pitney Bowes has been innovating and delivering technologies that remove the complexity of getting commerce transactions precisely right. For additional information visit Pitney Bowes at www.pitneybowes.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005150/en/

John Spadafora

Pitney Bowes

M+1 518 708 3466

[email protected]

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Technology Security Transport Software Hardware Data Management Logistics/Supply Chain Management Supply Chain Management Retail Online Retail

MEDIA:

Logo